FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3129815024> ?p ?o ?g. }

• W3129815024 endingPage "29" @default.
• W3129815024 startingPage "PS6" @default.
• W3129815024 abstract "Abstract Purpose The accurate assessment of residual tumor tissue after neoadjuvant chemotherapy (NAC) for breast cancer is closely related to the subsequent treatment and prognosis of patients. Currently commonly used assessment methods, including Miller and Payne system (MPS), Residual Cancer Burden (RCB), and Residual Disease in Breast and Nodes (RDBN) assessment system, etc., have certain limitations in terms of accurate evaluation and determining prognosis. The limitation of MPS lies in the need to review the original tumor biopsy specimen and compare the cell contents of the biopsy specimen and the surgical specimen. The limitation of RCB is that it requires a broader sampling, as well as more time and energy in microscopic examination. Furthermore, determining the number of cells is subjective and differences exist among observers. The limitation of RDBN is its poor correlation with prognosis. Ki-67, as a marker to reflect cell proliferation, is widely used in prognostic judgment of invasive breast cancer and is also an important reference in treatment decision-making. This study aimed to combine the Ki-67 expression status after NAC with RDBN to design a new pathological assessment method, which we called residual disease in breast and nodes combined with Ki-67 (RDBN-K), and to study its significance for the prognosis of patients.Methods RDBN-K = 0.2 (residual breast tumor size in centimeters) + index of involved nodes + tumor histological grade+ index of Ki-67. The residual tumor size, index of involved nodes, and histological grade are the same as RDBN. The index of Ki-67 is scored as 0 for less than 14% and 1 for greater than or equal to 14%. The residual diseases of 723 patients with TNM staging of stage II to stage III who had undergone NAC and surgical treatment were evaluated by RDBN-K. RDBN-K includes 4 risk levels (levels 1-4) according to residual disease magnitude after neoadjuvant chemotherapy. The RDBN-K levels were defined as follows: RDBN-K-1 (equivalent to pCR) is an index of 0, RDBN-K-2 is an index between 0.1 and 3, RDBN-K-3 is an index between 3.1 and 5.3, and RDBN-4 is an index 5.4 or more. At the same time, RDBN was used to evaluate the residual disease of all patients after NAC. This study followed up the survival status of 723 patients. After combining the prognoses, the accuracy and clinical significance of the RDBN and RDBN-K were compared.Results During the follow-up, in the entire cohort, 147 (20.3%) recurrences or metastases were observed; local recurrence was 58 (8.0%), distant metastasis was 103 (14.2%), and 69 (9.5%) patients died. Among the RDBN-2 cases, 40 (5.5%) of 122 cases were reclassified to RDBN-K-3. Among the RDBN-3 cases, 17 (2.4%) of 295 cases were reclassified: 2 cases were reclassified to RDBN-K-4, and 15 cases were reclassified to RDBN-K-2. Among the 220 cases in the RDBN-4 category, 40 (5.5%) were reclassified to the RDBN-K-3 category using the RDBN-K calculation. Over the follow-up period, 13.6% of patients in the RDBN-4 category died, and 15.9% of patients in the RDBN-K-4 category died. RDBN and RDBN-K showed statistically significant differences in the disease-free survival (DFS) and overall survival (OS) of all patients (P values are all less than 0.05). Pairwise stratified analysis showed that the differences in DFS and OS between RDBN-K-3 and RDBN-K-4 (DFS: P = 0.019, OS: P = 0.035) were greater than that between RDBN-3 and RDBN-4 (DFS: P = 0.052, OS: P = 0.214), and the differences in OS between RDBN-K-2 and RDBN-K-3 (P = 0.023) were greater than that between RDBN-2 and RDBN-3 (P = 0.157).Conclusion Compared with RDBN, RDBN-K is more accurate in assessing the residual tumor burden after breast cancer NAC and predicting the prognosis for breast cancer patients, and provides more basis for follow-up intensive treatment of patients. Citation Format: Ruoqi Han, Yueping Liu, Yanqi Ma, Zhikun Liu, Chunxiao Li, Cuizhi Geng. A new pathological assessment method to assess residual lesions after neoadjuvant chemotherapy for breast cancer: Residual disease in breast and nodes combined with Ki-67 (RDBN-K) [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS6-29." @default.
• W3129815024 created "2021-03-01" @default.
• W3129815024 creator A5006768285 @default.
• W3129815024 creator A5050067556 @default.
• W3129815024 creator A5055529791 @default.
• W3129815024 creator A5084959058 @default.
• W3129815024 creator A5088953253 @default.
• W3129815024 creator A5090012174 @default.
• W3129815024 date "2021-02-15" @default.
• W3129815024 modified "2023-10-06" @default.
• W3129815024 title "Abstract PS6-29: A new pathological assessment method to assess residual lesions after neoadjuvant chemotherapy for breast cancer: Residual disease in breast and nodes combined with Ki-67 (RDBN-K)" @default.
• W3129815024 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps6-29" @default.
• W3129815024 hasPublicationYear "2021" @default.
• W3129815024 type Work @default.
• W3129815024 sameAs 3129815024 @default.
• W3129815024 citedByCount "0" @default.
• W3129815024 crossrefType "journal-article" @default.
• W3129815024 hasAuthorship W3129815024A5006768285 @default.
• W3129815024 hasAuthorship W3129815024A5050067556 @default.
• W3129815024 hasAuthorship W3129815024A5055529791 @default.
• W3129815024 hasAuthorship W3129815024A5084959058 @default.
• W3129815024 hasAuthorship W3129815024A5088953253 @default.
• W3129815024 hasAuthorship W3129815024A5090012174 @default.
• W3129815024 hasConcept C11413529 @default.
• W3129815024 hasConcept C121608353 @default.
• W3129815024 hasConcept C126322002 @default.
• W3129815024 hasConcept C126838900 @default.
• W3129815024 hasConcept C142724271 @default.
• W3129815024 hasConcept C143998085 @default.
• W3129815024 hasConcept C155512373 @default.
• W3129815024 hasConcept C204232928 @default.
• W3129815024 hasConcept C207886595 @default.
• W3129815024 hasConcept C2775934546 @default.
• W3129815024 hasConcept C2776694085 @default.
• W3129815024 hasConcept C2777751288 @default.
• W3129815024 hasConcept C2778292576 @default.
• W3129815024 hasConcept C2779134260 @default.
• W3129815024 hasConcept C2779823535 @default.
• W3129815024 hasConcept C2780007613 @default.
• W3129815024 hasConcept C2910938049 @default.
• W3129815024 hasConcept C41008148 @default.
• W3129815024 hasConcept C530470458 @default.
• W3129815024 hasConcept C71924100 @default.
• W3129815024 hasConceptScore W3129815024C11413529 @default.
• W3129815024 hasConceptScore W3129815024C121608353 @default.
• W3129815024 hasConceptScore W3129815024C126322002 @default.
• W3129815024 hasConceptScore W3129815024C126838900 @default.
• W3129815024 hasConceptScore W3129815024C142724271 @default.
• W3129815024 hasConceptScore W3129815024C143998085 @default.
• W3129815024 hasConceptScore W3129815024C155512373 @default.
• W3129815024 hasConceptScore W3129815024C204232928 @default.
• W3129815024 hasConceptScore W3129815024C207886595 @default.
• W3129815024 hasConceptScore W3129815024C2775934546 @default.
• W3129815024 hasConceptScore W3129815024C2776694085 @default.
• W3129815024 hasConceptScore W3129815024C2777751288 @default.
• W3129815024 hasConceptScore W3129815024C2778292576 @default.
• W3129815024 hasConceptScore W3129815024C2779134260 @default.
• W3129815024 hasConceptScore W3129815024C2779823535 @default.
• W3129815024 hasConceptScore W3129815024C2780007613 @default.
• W3129815024 hasConceptScore W3129815024C2910938049 @default.
• W3129815024 hasConceptScore W3129815024C41008148 @default.
• W3129815024 hasConceptScore W3129815024C530470458 @default.
• W3129815024 hasConceptScore W3129815024C71924100 @default.
• W3129815024 hasIssue "4_Supplement" @default.
• W3129815024 hasLocation W31298150241 @default.
• W3129815024 hasOpenAccess W3129815024 @default.
• W3129815024 hasPrimaryLocation W31298150241 @default.
• W3129815024 hasRelatedWork W2042350842 @default.
• W3129815024 hasRelatedWork W2053631619 @default.
• W3129815024 hasRelatedWork W2366924143 @default.
• W3129815024 hasRelatedWork W2400747471 @default.
• W3129815024 hasRelatedWork W2617377136 @default.
• W3129815024 hasRelatedWork W3013422066 @default.
• W3129815024 hasRelatedWork W3148055880 @default.
• W3129815024 hasRelatedWork W3174328103 @default.
• W3129815024 hasRelatedWork W3214589972 @default.
• W3129815024 hasRelatedWork W4381057421 @default.
• W3129815024 hasVolume "81" @default.
• W3129815024 isParatext "false" @default.
• W3129815024 isRetracted "false" @default.
• W3129815024 magId "3129815024" @default.
• W3129815024 workType "article" @default.